Expression of the macrophage immunometabolism regulator gene (MACIR) is associated 12 with severity of autoimmune disease pathology and the regulation of macrophage biology 13 through unknown mechanisms. The 206 amino acid protein lacks homology to any 14 characterized protein sequence and is a disordered protein according to structure prediction 15
Introduction 25
MACIR, previously named C5orf30, is a negative regulator of tissue damage and 26 inflammation in rheumatoid arthritis (RA). It is highly expressed in the synovium of 27 rheumatoid arthritis patients where it is predominately expressed by fibroblasts and 28 macrophages (1) . Reduced MACIR expression is an early event in the pathogenesis of RA 29
and is negatively correlated with both Disease Activity Score for Rheumatoid Arthritis with 30 ESR (DAS-ESR) and synovial Tumor Necrosis Factor (TNF) expression in early RA patients 31
(2). Loss of expression contributes to the pathology of inflammatory arthritis in vivo, with 32 inhibition of MACIR in the collagen-induced arthritis model leading to accentuated joint 33 inflammation and tissue damage, and an increased inflammatory phenotype in a zebrafish 34 model of wound healing (1, 2) . MACIR regulates macrophage cell phenotype, with increased 35 MACIR expression found in M2-like anti-inflammatory macrophages. Its activity is regulated 36 by multiple mechanisms in response to immune stimulants that include transcriptional and 37 post-translational modifications and differential protein turn over (2). Inhibition of MACIR 38 expression reduces wound healing/repair-associated functions of macrophages, reduces 39 signaling required for resolution of inflammation, and decreases secretion of anti-40 inflammatory mediators (2). The ability of MACIR to negatively regulate inflammation is due, 41
at least in part, to its role in regulating macrophage immunometabolism. In addition, recent 42 evidence from the Human Pathology Atlas indicates that MACIR may be an unfavourable 43 prognostic marker in liver and endometrial cancer. A CCNH: MACIR fusion was identified as 44 a recurrent fusion gene across multiple cancer types (3-5). Thus, understanding more about 45 the function of MACIR has wide ranging implications for health and disease. 46 47 species. However sequence analysis fails to identify homology to another vertebrate gene or 48
protein. Modelling of protein secondary structure indicates that the protein is disordered 49 without significant -helical or -sheet content preventing informative structure function 50 analysis. Identifying mechanisms behind the function of this protein in the cell can be 51 approached without this information through the identification of protein-protein interaction 52 networks, their subcellular localization and the characterization of specific motifs and amino 53 acids in the MACIR protein mediating these interactions. 54
In this study we have employed a membrane solubilization buffer (MSB) to enrich proteins 55 from all cellular compartments from transfected HEK293T cells prior to pull down of affinity 56 tagged MACIR and quantitative mass spectrometry analysis. We have previously developed 57 a calcium-dependent fragment complementation-based affinity pull down system that used 58 the highly specific recognition between two peptide fragments, EF1 & EF2, of a small 59 calcium binding protein to pull down overexpressed kinase proteins from HEK293T cells and 60 7 transmembrane proteins from Escherichia coli membranes using MSB. This buffer 61 contains a high concentration of glycerol and a cocktail of detergents to disrupt cellular and 62 intracellular membranes and stabilise membrane proteins in detergent micelles (6,7). Protein 63 complexes are eluted from the affinity matrix through calcium chelation and dissociation of 64 the EF peptides prior to digestion and MS analysis, improving the signal to noise ratio for the 65 identification of significant interactions. We then validate specific MACIR interactions with 66 immunoprecipitation and use mutational analysis to characterize interacting motifs. 67
Results & Discussion 68

Affinity pull down of EF1-MACIR in RIPA & MSB 69
To determine the optimum conditions for pull down of MACIR interactors we performed 70 western blot analysis of EF2 agarose pull downs of EF1-MACIR from normalised total 71 protein lysates prepared with two cell lysis buffer formulations. MSB enriched more EF1-72 MACIR protein for pull down than RIPA buffer and the total amount of pulled down protein 73 was also enhanced ( Figure 1A i & ii). The empty vector control lysate and pull down for MSB 74 is shown for comparison ( Figure 1A iii). For mass spectrometry analysis proteins were eluted 75 from the agarose prior to preparing peptides with tryptic digestion, followed by label-free 76 quantitative mass spectrometry. Significant interactors were identified by dividing the 77 average LFQ intensities found in the EF1-tagged MACIR samples by those identified in the 78 EF1-tagged empty vector control. An LFQ intensity ratio greater than 2 with a p-value of less 79 than 0.05 following t-test analysis was considered significant (8,9,10). A total of 9 proteins 80
were identified as significant interactors in RIPA buffer pull downs, while these 9 proteins 81
and 54 others were identified in MSB prepared lysates ( Figure 1B , Table S1 ). RIPA buffer is 82 commonly used to solubilize cells for immunoprecipitation and affinity pull down based mass 83 spectrometry studies but it is clear from our data that a number of significant interactions 84 with membrane bound proteins e.g., the mitochondrial ATP synthase subunits ATP5C1, 85
ATP5L and ATP5A1, and proteins from membrane bound organelles e.g., nuclear PRKDC, 86
would not have been identified without MSB cell lysis. The top 20 interactors identified with 87 this approach, ranked by LFQ ratio, showed that in addition to the cytosolic proteins 88 UNC119B and 14-3-3 proteins (YWAH, YWHAE and YWAHG) identified in both buffer 89 conditions, the majority of interacting proteins were from nuclear and mitochondrial 90 compartments identified in the MSB samples ( Figure 1C ). 91 14-3-3 protein isoforms are adapter proteins implicated in regulating a large number of 92 general and specialized signaling pathways usually by recognition of a phosphoserine or 93 phosphothreonine motif. They are likely to interact with MACIR via phosphoserine residues 94 at positions 38 and 49 that are both confirmed in phosphopeptide mass spectrometry 95 analysis (11) and are both predicted to be within 14-3-3 binding motifs (12) and manually 96 curated linear motif database motifs (13). ranked by LFQ intensity ratio with proteins identified in MSB alone identified in yellow and in 106 both buffers in blue. 107
Immunoprecipitation validation of TNPO1 & UNC119 interactions with FLAG-MACIR 108
To confirm the specificity of the interactions identified with the mass spectrometry-based 109 approach we next immunoprecipitated FLAG-tagged MACIR with anti-FLAG M2 sepharose 110 beads and detected the co-precipitation of TNPO1 (Figure 2A i), and UNC119A and B ( Fig  111  2A ii) from transfected HEK293T cell lysates. Anti-MACIR and anti-FLAG antibody controls 112 confirmed specificity (Fig 2A ii) of the method. The interaction with UNC119 proteins 113 confirms a previously reported interaction in a proteomics dataset in HEK293T cells (14). In 114 the cell UNC119B has been shown to be required for localization of myristoylated proteins 115 (15), while UNC119A cargo localization has been shown to regulate T-cell and macrophage 116 signaling activities (16). TNPO1 is a transport receptor that transports substrates from the 117 cytoplasm to the nucleus through nuclear pore complexes by recognizing nuclear 118 (ii) (iii) A. (i) 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 RIPA MSB B. of what is the function of MACIR in the nucleus. To confirm that it does localize to the 120 nucleus in HEK293T cells we studied endogenous MACIR distribution with 121 immunocytochemistry and confocal microscopy. Imaging of anti-MACIR stained HEK293T 122 cells confirmed that MACIR is localized to the nucleus as well as the cytoplasm ( Figure 2B ). 
LFQ
antibodies (ii) anti-FLAG IP of FLAG-MACIR and probing with anti-UNC119A and UNC119B 128
antibodies and anti-FLAG antibody controls. (B) Confocal imaging of anti-MACIR staining in 129
HEK293T cells at 60X magnification 130 TNPO1 recognizes cargo for import to the nucleus via PY-NLS motifs that are structurally 131 disordered in free substrates, have overall basic character, and possess a central 132 hydrophobic or basic motif followed by a C-terminal R/H/KX(2-5)PY consensus sequence 133
(17). We analysed two candidate consensus TNPO1 binding sites in the primary sequence 134
of MACIR (Fig 2A) , that were previously described in other TNPO1 substrate proteins 135
(17,18). We mutated proline/tyrosine (PY) residues to alanine/glutamine and analysed 136 TNPO1 co-immunoprecipitation with FLAG-tagged MACIR P116A/Y117Q and MACIR 137 P142A/Y143Q mutants. Our results show that TNPO1 binding to the MACIR P116/Y117Q 138 mutant is lost while binding to P142A/Y143Q mutant is maintained, confirming that TNPO1 139 binds to MACIR via the PY-NLS recognition motif at amino acid positions 98-117 ( Fig 2B i) . 140
Finally, we probed the subcellular fractions from these transfected cells with anti-MACIR and 141
show a dysregulation of the subcellular localization of the P116A/Y117Q mutant with 142 cytosolic accumulation of the mutant protein ( Fig 2B ii) . with anti-MACIR. 150
Conclusion 151
Our previous research has highlighted the potential for pro-resolution signaling in 152 macrophages as a novel therapeutic target. Therapeutic agents that regulate localization of 153
MACIR to particular sub-compartments may in the future yield pro-resolution treatments in 154 inflammatory diseases such as rheumatoid arthritis. Identification of MACIR in the nucleus 155
and characterization of a specific interaction with the nuclear receptor protein TNPO1 in this 156 study highlights a promising avenue of future investigation in macrophage and fibroblast 157 cells. 158
Materials and Methods 159
Chemicals and reagents. complex mixture was incubated for 20 minutes at room temperature. Samples were then 185 added drop-wise to pre-warmed media containing 10% FBS without penicillin and 186 streptomycin and agitated. Cells were incubated at 37°C for 24 hours. 187
Harvesting and lysis of cells 188
Cells were washed twice with PBS. Cells were harvested in 750 μl of RIPA (20 mM Tris-HCl, 189 150 mM NaCl, 1% Deoxycholic acid, 1% NP-40, 2 mM CaCl 2 , phosphatase and protease 190 inhibitors) or MSB (50 mM Tris-HCl, 200 mM NaCl, 0.5% CHAPS, 0.1% CHS, 1% DDM, 191 30% Glycerol, 2 mM CaCl 2 , pH 7.5 and phosphatase and protease inhibitors) per 10 cm 3 192 dish using a cell scraper. Cell pellets were mechanically disrupted via aspiration through a 193 21-gauge needle in the lysis buffer. Cells were centrifuged at 10,000 x g for 10 minutes at 194 4°C, retaining the supernatant. The total protein concentration was determined using 195 bicinchoninic acid (BCA) assay (Pierce) and concentrations normalised for samples used in 196 subsequent analyses. 197
Affinity pull-down of EF1-MACIR from transfected lysates 198
EF2 agarose and unconjugated control beads were collected by centrifugation at 1,000 x g 199 for 1 minute at 4°C. Beads were washed five times in 1 ml lysis buffer and 1.5 mg of lysate 200 samples were precleared by incubation at 4°C for 1 hour using non-conjugated beads. The 201 agarose beads were collected by centrifugation at 5,000 x g at 4°C for 1 minute and the 202 supernatant was retained. The precleared lysate was incubated overnight at 4°C with EF2 203 agarose beads or non-conjugated beads as a negative control. Following incubation, 204 samples were collected by centrifugation at 5,000 x g for 1 minute at 4°C. Samples were 205
washed five times in lysis buffer. Following wash procedure, EF1-MACIR was eluted from 206 the EF2-agarose beads using elution buffer (RIPA or MSB + 10 mM EDTA) by resuspension 207
and allowing samples to incubate for 5 minutes at room temperature. Beads were collected 208 by centrifugation at 5,000 x g for 1 minute and the supernatant was collected. Elution was 209 repeated 5 times. Samples were stored at -80°C prior to further analysis. 210
Mass Spectrometry Sample preparation: 211
Samples were mixed with 400 μl of 8 M urea in 0.1 M Tris-HCl, pH 8.9 using a clean wetting solution (50% acetonitrile in 0.1% trifluoroacetic acid) twice prior to collection at 227 10,000 rpm for 5 min. Protein from the tryptic digest supernatants was aspirated and 228 dispensed up to 10 times and washing solution (0.1% trifluoroacetic acid in ddH 2 O) was 229 aspirated and dispensed twice through the ZipTip. 10 μL of elution solution (50% acetonitrile 230 in 0.1% trifluoroacetic acid) was dispensed into a clean tube followed by aspiration and 231 dispensing of the sample through the ZipTip at least 3 times without the introduction of air. 232
Samples were evaporated on a CentriVap Concentrator for 10-15 min, allowing for a small 233 retentate volume (6 μL). The sample was finally resuspended in 20 μL of 0.1% formic acid 234
and centrifuged for 5 min at 15,000 rpm. 16 μL of this sample was transferred to a clean 235 mass spectrometry vial for analysis. 236
Mass spectrometry: 237
Mass spectrometry was performed using an Ultimate3000 RSLC system that was coupled to 238
an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific). Following tryptic 239 digest, the peptides were loaded onto a nano-trap column (300 μm i.d x 5mm precolumn that 240
was packed with Acclaim PepMap100 C18, 5 μm, 100 Å; Thermo Scientific) running at a 241 flow rate of 30 μl/min in 0.1% trifluoroacetic acid made up in HPLC water. The peptides were 242 eluted and separated on the analytical column (75 μm i.d. × 25 cm, Acclaim PepMap RSLC 243 C18, 2μm, 100 Å; Thermo Scientific) after 3 minutes by a linear gradient from 2% to 30% of 244 buffer B (80% acetonitrile and 0.08% formic acid in HPLC water) in buffer A (2% acetonitrile 245 and 0.1% formic acid in HPLC water) using a flow rate of 300 nl/min over 150 minutes. The 246 remaining peptides were eluted using a short gradient from 30% to 95% in buffer B for 10 247 minutes. The mass spectrometry parameters were as follows: for full mass spectrometry 248 spectra, the scan range was 335-1500 with a resolution of 120,000 at m/z=200. MS/MS 249 acquisition was performed using top speed mode with 3 seconds cycle time. Maximum 250 injection time was 50 ms. The AGC target was set to 400,000, and the isolation window was 251 1 m/z. Positive Ions with charge states 2-7 were sequentially fragmented by higher energy 252 collisional dissociation. The dynamic exclusion duration was set at 60 seconds and the lock 253 mass option was activated and set to a background signal with a mass of 445.12002. 254
Analysis of mass spectrometry data: 255
MS data analysis was performed using MaxQuant (version 1.5.3.30). Trypsin was set to be 256
the digesting enzyme with maximal 2 missed cleavages. Cysteine carbamidomethylation 257
was set for fixed modifications, and oxidation of methionine and N-thermal acetylation were 258 specified as variable modifications. The data was then analysed with the minimum ratio 259 count of 2. The first search peptide was set to 20, the main search peptide tolerance to 5 260 ppm and the 2re-quantify2 option was selected. For protein and peptide identification the 261
Human subset of the SwissProt database (Release 2015_12) was used and the 262 contaminants were detected using the MaxQuant contaminant search. A minimum peptide 263
number of 1 and a minimum of 6 amino acids was tolerated. Unique and razor peptides were 264
used for quantification. The match between run option was enabled with a match time 265 window of 0.7 minutes and an alignment window of 20 minutes. A statistical analysis of the 266 cut off ratio and two-sample t-test was done to determine interactors. Anti-Rabbit 1/600 dilution) for two hours at room temperature, washed with PBS and a #1. 
